Panel of Bloodstream MicroRNAs Predicts Damage from Radiation Exposure
|
By LabMedica International staff writers Posted on 25 May 2015 |
A panel of microRNAs (miRNAs) that can be measured in blood samples is able to predict the extent of long-term radiation injury and likelihood of survival following exposure to high doses of radiation.
Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.
Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.
MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.
The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.
The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.
By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.
"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."
The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.
Related Links:
Dana-Farber Cancer Institute
Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.
Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.
MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.
The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.
The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.
By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.
"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."
The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.
Related Links:
Dana-Farber Cancer Institute
Latest Pathology News
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








